Phase II study of doxycycline at a daily dose of 50 mg or 100 mg for the prevention of skin toxicity in patients with metastatic colorectal cancer treated with panitumumab and chemotherapy
INDEPENDENT CLINICAL TRIAL
Clinical trial information
- Promoter: CRIS FOUNDATION FOR RESEARCH TO BEAT CANCER
- Phase: II
- Execution start: 07/03/2018
- End of execution: 30/04/2020
- IP: BEATRIZ GONZALEZ ASTORGA